Alkermes Schizophrenia Drug Heads To FDA, But Questions Linger

Alkermes got some much-needed good news on Thursday, announcing that an experimental schizophrenia drug fared better than a staple drug for the debilitating disease in a closely watched study. But is that benefit big enough for doctors to prescribe the drug, if it’s approved, over cheap generics?